CIK 0001636651 · Non-accelerated filer<br>Smaller reporting company
Ovid Therapeutics Inc.
Sign in to watch- Ticker
- OVID
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 465270895
- Phone
- 212-776-4381
- Business address
- 441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY, 10001
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 61 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-04-08 | Perone Thomas Michael General Counsel, Secretary | Grant or award · Stock Option (Right to Buy) | +25,399 | 25,399 | ||
| 2022-04-08 | Perone Thomas Michael General Counsel, Secretary | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2022-04-08 | Duncan Barbara Gayle Director | Grant or award · Stock Option (Right to Buy) | +21,347 | 21,347 | ||
| 2022-04-08 | Bernstein Karen Director | Grant or award · Stock Option (right to buy) | +69,424 | 69,424 | ||
| 2022-02-03 | Poole Robert Michael Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2022-02-03 | Friedman Bart Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2022-02-03 | Fitzgerald Kevin Joseph Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2022-02-03 | Duncan Barbara Gayle Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2022-02-03 | Bernstein Karen Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2022-02-03 | Tardio Jason Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +175,000 | 175,000 | ||
| 2022-02-03 | Rona Jeffrey A CBFO | Grant or award · Stock Option (Right to Buy) | +218,750 | 218,750 | ||
| 2022-02-03 | Perone Thomas Michael General Counsel, Secretary | Grant or award · Stock Option (Right to Buy) | +175,000 | 175,000 | ||
| 2022-02-03 | LEVIN JEREMY M CEO | Grant or award · Stock Option (Right to Buy) | +600,000 | 600,000 | ||
| 2021-10-06 | Fitzgerald Kevin Joseph Director | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2021-07-14 | Rakhit Amit President and CMO | Option exercise | +34,017 | $1.89 | $64K | 760,840 |
| 2021-07-14 | Rakhit Amit President and CMO | Sale | −34,017 | $3.71 | $126K | 726,823 |
| 2021-07-14 | Rakhit Amit President and CMO | Option exercise · Stock Option (Right to Buy) | +34,017 | 90,983 | ||
| 2021-07-09 | Poole Robert Michael Director | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2021-07-01 | Tardio Jason Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 | ||
| 2021-06-11 | Duncan Barbara Gayle Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 |
Page 5 of 7 · 123 trades